Prevention of bacterial infection in pediatric oncology: What do we know, what can we learn?

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 16-20

  Alexander, Sarah ^a   Nieder, Michael ^b   Zerr, Danielle M ^c   Fisher, Brian T ^d   Dvorak, Christopher C ^e   Sung, Lillian ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacteria; Cancer; Children; Infection; Prevention

Indexed keywords

ALCOHOL; AMOXICILLIN PLUS CLAVULANIC ACID; CEPHALOSPORIN; CHLORHEXIDINE GLUCONATE; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; HEPARIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTISEPSIS; ARTHRALGIA; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BATH; BLOODSTREAM INFECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CATHETER INFECTION; CATHETER REMOVAL; CHILDHOOD CANCER; CHILDHOOD DISEASE; CHILDHOOD MORTALITY; CLOSTRIDIUM DIFFICILE INFECTION; DRUG FEVER; DRUG SAFETY; ENTEROBACTERIACEAE INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HYGIENE; INFECTION; INFECTION PREVENTION; INFECTION RISK; META ANALYSIS (TOPIC); MICROFLORA; MUSCULOSKELETAL DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SKIN CARE; STREPTOCOCCUS INFECTION; TENDINITIS; TENDON RUPTURE;

ADOLESCENT; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFECTION CONTROL; MALE; NEOPLASMS; RISK FACTORS; SEPSIS;

EID: 84861216308     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23416     Document Type: Review

References (74)

1. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258-2266;.
2. Sung L, Aplenc R, Zaoutis T, et al. Infections in pediatric acute myeloid leukemia: Lessons learned and unresolved questions. Pediatr Blood Cancer 2008; 51: 458-460;.
3. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384-4393;.
4. Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 2007; 110: 3532-3539;.
5. Saarinen-Pihkala UM, Heilmann C, Winiarski J, et al. Pathways through relapses and deaths of children with acute lymphoblastic leukemia: Role of allogeneic stem-cell transplantation in Nordic data. J Clin Oncol 2006; 24: 5750-5762;.
6. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90. J Clin Oncol 2010; 28: 2339-2347;.
7. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol 2008; 26: 3971-3978;.
8. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 2000; 96: 1709-1715;.
9. Lawson SE, Harrison G, Richards S, et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: A report on the medical research council UKALLR1 study. Br J Haematol 2000; 108: 531-543;.
10. Thomson B, Park JR, Felgenhauer J, et al. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatr Blood Cancer 2004; 43: 571-579;.
11. Wingard JR, Leather HL. Bacterial infections. In: Appelbaum FR, Forman SJ, Blume KG, editors. Thomas' hematopoietic cell transplantation. 3rd edition. Malden, MA: Blackwell Sciences; 2004.
12. Castagnola E, Faraci M. Management of bacteremia in patients undergoing hematopoietic stem cell transplantation. Expert Rev Anti-infective Ther 2009; 7: 607-621;.
13. Busca A, Saroglia EM, Giacchino M, et al. Analysis of early infectious complications in pediatric patients undergoing bone marrow transplantation. Support Care Cancer 1999; 7: 253-259;.
14. Castagnola E, Bagnasco F, Faraci M, et al. Incidence of bacteremias and invasive mycoses in children undergoing allogeneic hematopoietic stem cell transplantation: A single center experience. Bone Marrow Transpl 2008; 41: 339-347;.
15. Castagnola E, Faraci M, Moroni C, et al. Bacteremias in children receiving hemopoietic SCT. Bone Marrow Transpl 2008; 41: S104-S106;.
16. Mullen CA, Nair J, Sandesh S, et al. Fever and neutropenia in pediatric hematopoietic stem cell transplant patients. Bone Marrow Transpl 2000; 25: 59-65;.
17. Cappellano P, Viscoli C, Bruzzi P, et al. Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantion. New Microbiol 2007; 30: 89-99;.
18. Poutsiaka DD, Price LL, Ucuzian A, et al. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transpl 2007; 40: 63-70;.
19. Almyroudis NG, Fuller A, Jakubowski A, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 2005; 7: 11-17;.
20. Hammond SP, Baden LR. Antibiotic prophylaxis for patients with acute leukemia. Leuk Lymphoma 2008; 49: 183-193;.
21. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-987;.
22. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-998;.
23. Gafter-Gvili A, Fraser A, Paul M, et al. Meta-analysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-995;.
24. Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: New evidence, practical decisions. Cancer 2006; 107: 1743-1751;.
25. Eleutherakis-Papaiakovou E, Kostis E, Migkou M, et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: Results of a single institution, randomized phase 2 trial. Am J Hematol 2010; 85: 863-867;.
26. Guthrie KA, Yong M, Frieze D, et al. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl 2010; 45: 675-681;.
27. Kroschinsky F, Wichmann G, Bornhauser M, et al. Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazabactam in patients undergoing hematopoietic stem cell transplantation. Transpl Infect Dis 2002; 2: 132-136;.
28. Perez-Simon JA, Garcia-Escobar I, Martinez J, et al. Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. Bone Marrow Transpl 2004; 33: 183-187;.
29. Slavin MA, Grigg AP, Schwarer AP, et al. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation. Bone Marrow Transpl 2007; 40: 157-163;.
30. Solano C, Gutierrez A, Martinez F, et al. Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation: A matched pair study comp[aring orla flouroquinolone and intravenous pipericillin-tazobactam. Bone Marrow Tranplant 2005; 36: 59-65;.
31. Castagnola E, Boni L, Giacchino M, et al. A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J 2003; 22: 359-365;.
32. Pizzo PA, Robichaud KJ, Edwards BK, et al. Oral antibiotic prophylaxis in patients with cancer: A double-blind randomized placebo-controlled trial. J Pediatr 1983; 102: 125-133;.
33. van Eys J, Berry DM, Crist W, et al. Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer 1987; 59: 19-23;.
34. Yousef AA, Fryer CJ, Chedid FD, et al. A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2004; 43: 637-643;.
35. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 2008; 113: 376-382;.
36. Nijssen S, Fluit A, van de Vijver D, et al. Effects of reducing beta-lactam antibiotic pressure on intestinal colonization of antibiotic-resistant gram-negative bacteria. Intens Care Med 2010; 36: 512-519;.
37. Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972; 77: 707-714;.
38. Tancrede CH, Andremont AO. Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 1985; 152: 99-103;.
39. Wingard JR, Dick J, Charache P, et al. Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. Antimicrob Agents Chemother 1986; 30: 435-439;.
40. Cattaneo C, Casari S, Bracchi F, et al. Recent increase in enterococci, viridans Streptococci, Pseudomonas spp. and multiresistant strains among haematological patients, with a negative impact on outcome. Results of a 3-year surveillance study at a single institution. Scand J Infect Dis 2010; 42: 324-332;.
41. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-118;.
42. Prabhu RM, Piper KE, Litzow MR, et al. Emergence of quinolone resistance among viridans group Streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005; 24: 832-838;.
43. Razonable RR, Litzow MR, Khaliq Y, et al. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 2002; 34: 1469-1474;.
44. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis 2005; 40: 1087-1093;.
45. Therriault BL, Wilson JW, Barreto JN, et al. Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc 2010; 85: 711-718;.
46. van Vliet MJ, Tissing WJ, Dun CA, et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis 2009; 49: 262-270;.
47. von Baum H, Sigge A, Bommer M, et al. Moxifloxacin prophylaxis in neurotropenic patients. J Antimicrob Chemother 2006; 58: 891-894;.
48. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the Unites States, 2001-2006. Pediatrics 2008; 122: 1266-1270;.
49. Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol 2009; 147: 125-128;.
50. Owens RCJ, Ambrose PG. Antimicrobial safety: Focus on fluroquinolones. Clin Infect Dis 2005; 41: SI44-S157;.
51. Corrao G, Zambon A, Bertu L, et al. Evidence od tendinitis provoked by fluoroquinolone treatment: A case-control study. Drug Saf 2006; 29: 889-896;.
52. Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 2007; 26: 865-867;.
53. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: Worldwide clinical experience based on compassionate use-Safety report. Pediatr Infect Dis J 1997; 16: 127-129;.
54. Jick S. Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J 1997; 16: 130-133;; discussion 133-134, 160-132.
55. Redmond AO. Risk-benefit experience of ciprofloxscin use in pediatric patients in the United Kingdom. Pediatr Infect Dis J 1997; 16: 147-149;; discussion 160-142.
56. Noel GJ, Blumer JL, Pichichero ME, et al. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J 2008; 27: 483-489;.
57. Bradley JS, Arguedas A, Blumer JL, et al. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J 2007; 26: 868-878;.
58. Committee on Infectious Disease. The use of systemic fluoroquinolones. Pediatrics 2006; 118: 1287-1292;.
59. Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007; 26: 879-891;.
60. Freifeld A, Sankaranarayanan J, Ullrich F, et al. Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA. Support Care Cancer 2008; 16: 181-191;.
61. Lee SJ, Astigarraga CC, Eapen M, et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transpl 2008; 14: 1231-1238;.
62. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Prevention and Treatment of Cancer Related Infections. 2008.
63. Freifeld AG, Bow EJ, Ka S, et al. Clincal practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011; 52: 427-431;.
64. Engelhard D, Akova M, Boeckh MJ, et al. Bacterial infection prevention after stem cell transplantation. Bone Marrow Transpl 2009; 44: 467-470;.
65. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Reomm Rep 2002; 51: 1-29;.
66. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2011; 52: e162-e193;.
67. Bleasdale SC, Trick WE, Gonzalez IM, et al. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007; 167: 2073-2079;.
68. Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: Results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37: 1858-1865;.
69. Popovich KJ, Hota B, Hayes R, et al. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 2009; 30: 959-963;.
70. Vernon MO, Hayden MK, Trick WE, et al. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: The effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006; 166: 306-312;.
71. Henrickson KJ, Axtell RA, Hoover SM, et al. Prevention of central venous catheter-Related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. J Clin Oncol 2000; 18: 1269-1278;.
72. Safdar NMD. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: A meta-analysis of prospective, randomized trials. Clin Infec Dis 2006; 43: 474-484;.
73. Landry DLBG, Gobielle SL, Haessler SD, et al. Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 2010; 5: 1799-1804;.
74. Sanders JAP, Peter G, Lois S, et al. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother 2008; 62: 809-815;.